Mad Money with Jim Cramer - MAD CAP RECAP - The Official Mad Money Blog
RSS FEED
RECENT POSTS
- Lightning Round: Yahoo!, CEC Entertainment, Standard Pacific and More
- Cramer: Berkshire Hathaway Is a 'Screaming Buy'
- Kimco Realty CEO on Solid Earnings
- Cramer: Analysts Today Are So Negative
- Perrigo CEO on Earnings Beat
- Lightning Round: Pep Boys, Covidien, Goldman Sachs and More
- Buffalo Wild Wings Delivers Blazing Hot Quarter
- Wyndham CEO Talks Earnings
- What Keeps Cramer Up at Night
- Cramer's Fave Rail: Union Pacific or Norfolk Southern?
MAD MONEY FEATURES
PODCASTSWatch the Lightning Round whenever and wherever you want.
OFFICIAL MAD MONEY WIDGETGrab this all-in-one application and get recaps of the show sent right to your desktop or blog.
CRAMERS SOUNDBOARDAdmit it: You've always wanted to hit the "They
know nothing!" button. Here’s your chance.
CHECK OUT OUR PHOTOSCheck out Cramer on set, back to school, behind the scenes and more.
SHOP FOR MAD MERCHANDISEBuy Cramer books, bobbleheads and other Mad Money merchandise.
RING TONESPick up the phone! It's Cramer! New Mad Money sounds for your cell phone.
TEXT MESSAGE ALERTMad Money's mobile. Get show highlights sent to your phone.
Sanofi-Aventis Falling Off a Patent Cliff?
Text Size 
Web Editor, Mad Money
Sanofi-Aventis by its own admission has “a big patent-expiration problem,” Cramer said during Friday’s Mad Money. “And when drugs go off patent, pharmaceutical companies’ profits get obliterated.”
Drugs that accounted for about 41% of Sanofi-Aventis’ [SNY
Loading...
()
] 2009 sales could lose patent protection in the coming years, including its top two: the blood thinners, Plavix, which it shares with Bristol-Myers Squibb [BMY
Loading...
()
], and Lovenox. These drugs combined represent up to 9.7 billion euros in worldwide revenues.
Still, SNY claims that it has other treatments to carry the company in the meantime, namely the diabetes drug Lantus. And there’s Multaq for irregular heart rhythms, though it’s still too early to tell how big it will be. Sanofi also runs a strong vaccine division, which is number one in the word. Plus, Cramer said there’s a lot of promise in the company’s oncology pipeline, as much as any of the names he recommended during Mad Money’s cancer-research week. [33728388]
So is Sanofi-Aventis staring into a troubled future, or is Wall Street missing the company’s potential? Cramer went to CEO Chris Viehbacher to find out. Watch the video for the full interview.
Cramer’s charitable trust owns Bristol-Myers Squibb.
Call Cramer: 1-800-743-CNBC
Questions for Cramer?
Questions, comments, suggestions for the Mad Money website?
Data is a real-time snapshot *Data is delayed at least 15 minutes
